SMS Pharmaceuticals Limited SMSPHARMA NSEPHARMA
Healthcare · Drug Manufacturers - General · India
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
READ MORE ›₹369.25
+36.76% 1Y
Market & Price
Market Cap
₹3,458.10 Cr
Current Price
₹369.25
High / Low (52W)
₹438.30 / ₹214.42
Beta
0.40
Valuation
Stock P/E
33.12
Industry PE
37.60
Forward P/E
-
PEG Ratio
0.94
Book Value
₹81.83
Price to Book
4.51
P/S
3.90
EV/EBITDA
21.56
Dividend Yield
0.11%
Profitability & Returns
ROCE
13.84%
ROE
14.31%
ROA
6.53%
Profit Margin
11.50%
Op Margin
12.51%
EPS (Latest Qtr)
₹3.58
EPS (TTM)
₹11.15
Balance Sheet & Liquidity
Debt/Equity
0.46
Quick Ratio
0.74
Current Ratio
1.81
Debt
₹365.05 Cr
Total Assets
₹1,362.44 Cr
Current Assets
₹638.01 Cr
Working Capital
₹285.03 Cr
Ownership
Promoter Holding
75.55%
Chg in Prom Hold
-
FII / Inst Holding
2.98%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹3,693.17 Cr
Total Revenue (TTM)
₹886.87 Cr
EBITDA
₹171.28 Cr
Free Cash Flow
₹-95.11 Cr
Operating Cash Flow
₹59.22 Cr
Shares Outstanding
₹9.37 Cr
Gross Margin
34.14%
Payout Ratio
3.59%
Growth (CAGR)
Revenue 5Y
19.50%
Profit 5Y
514.92%
Revenue (YoY)
-4.10%
Earnings (YoY)
49.20%
PROS
- Compounding revenue at 19.5% over 5 years.
- Profit CAGR of 514.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SMSPHARMA SMS Pharmaceuticals Limited NSEPHARMA | 369.25 | 33.12 | ₹3,458.10 Cr | 0.11% | 13.84% | 14.31% | 19.50% | 514.92% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 248.20 Cr | 196.05 Cr | 242.43 Cr | 210.45 Cr | 237.95 Cr |
| Cost of Revenue | - | - | 171.74 Cr | 130.70 Cr | 165.56 Cr | 135.56 Cr | 156.66 Cr |
| Gross Profit | - | - | 76.45 Cr | 65.35 Cr | 76.87 Cr | 74.89 Cr | 81.28 Cr |
| Operating Expenses | - | - | 44.29 Cr | 35.73 Cr | 38.52 Cr | 41.26 Cr | 51.51 Cr |
| Operating Income | - | - | 32.17 Cr | 29.62 Cr | 38.34 Cr | 33.63 Cr | 29.77 Cr |
| EBITDA | - | - | 42.23 Cr | 39.96 Cr | 49.80 Cr | 47.40 Cr | 42.47 Cr |
| Interest Expense | - | - | 5.07 Cr | 5.84 Cr | 5.74 Cr | 6.22 Cr | 5.28 Cr |
| Pretax Income | - | - | 28.52 Cr | 24.37 Cr | 34.04 Cr | 31.16 Cr | 27.07 Cr |
| Tax Provision | - | - | 8.44 Cr | 5.65 Cr | 8.91 Cr | 7.97 Cr | 6.10 Cr |
| Net Income | - | - | 20.31 Cr | 20.49 Cr | 25.31 Cr | 23.47 Cr | 32.71 Cr |
| Diluted EPS | - | - | 2.40 | 2.31 | 2.84 | 2.59 | 3.58 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 519.75 Cr | 706.46 Cr | 782.75 Cr | 886.87 Cr |
| Cost of Revenue | - | 390.61 Cr | 497.71 Cr | 518.05 Cr | 584.05 Cr |
| Gross Profit | - | 129.14 Cr | 208.75 Cr | 264.70 Cr | 302.83 Cr |
| Operating Expenses | - | 106.66 Cr | 123.50 Cr | 160.04 Cr | 171.47 Cr |
| Operating Income | - | 22.48 Cr | 85.25 Cr | 104.65 Cr | 131.36 Cr |
| EBITDA | - | 58.47 Cr | 120.24 Cr | 145.22 Cr | 179.63 Cr |
| Interest Expense | - | 20.99 Cr | 22.62 Cr | 18.54 Cr | 23.08 Cr |
| Pretax Income | - | 5.35 Cr | 66.11 Cr | 92.34 Cr | 116.64 Cr |
| Tax Provision | - | 1.47 Cr | 16.91 Cr | 24.94 Cr | 28.64 Cr |
| Net Income | - | -7.06 Cr | 49.83 Cr | 69.14 Cr | 101.99 Cr |
| Diluted EPS | 7.35 | -0.83 | 5.89 | 8.16 | - |
Compounded Sales Growth
| 5 Years: | 19.50% |
| 1 Year: | -4.10% |
Compounded Profit Growth
| 5 Years: | 514.92% |
| 1 Year: | 49.20% |
Stock Price Performance
| 1 Year: | +36.76% |
| 6 Months: | +30.99% |
| 3 Months: | -0.86% |
| 1 Month: | -5.38% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 879.61 Cr | 1,034.09 Cr | 1,152.68 Cr | 1,362.44 Cr |
| Current Assets | - | 410.65 Cr | 533.89 Cr | 554.47 Cr | 638.01 Cr |
| Cash & Equivalents | - | 7.31 Cr | 36.04 Cr | 41.40 Cr | 45.88 Cr |
| Inventory | - | 223.50 Cr | 233.70 Cr | 284.73 Cr | 351.21 Cr |
| Receivables | - | 148.35 Cr | 236.23 Cr | 203.23 Cr | 215.87 Cr |
| Total Liabilities | - | 419.08 Cr | 497.76 Cr | 513.04 Cr | 576.63 Cr |
| Current Liabilities | - | 254.91 Cr | 331.72 Cr | 324.37 Cr | 352.98 Cr |
| Long Term Debt | - | 121.13 Cr | 122.09 Cr | 139.36 Cr | 171.64 Cr |
| Total Debt | - | 254.07 Cr | 280.77 Cr | 310.76 Cr | 365.05 Cr |
| Total Equity | - | 460.53 Cr | 536.33 Cr | 639.64 Cr | 785.81 Cr |
| Shares Outstanding | - | 8.47 Cr | 8.47 Cr | 8.87 Cr | 9.37 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 22.45 Cr | 50.12 Cr | 81.71 Cr | 59.22 Cr |
| Investing Cash Flow | - | -29.76 Cr | -52.07 Cr | -123.43 Cr | -130.78 Cr |
| Financing Cash Flow | - | -31.97 Cr | 30.68 Cr | 47.08 Cr | 76.03 Cr |
| Capital Expenditure | - | -29.92 Cr | -52.16 Cr | -123.38 Cr | -130.56 Cr |
| Free Cash Flow | - | -7.47 Cr | -2.04 Cr | -41.67 Cr | -71.33 Cr |
| Net Change in Cash | - | -39.27 Cr | 28.73 Cr | 5.36 Cr | 4.48 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 24.8% | 29.5% | 33.8% | 34.1% |
| Operating Margin % | - | 4.3% | 12.1% | 13.4% | 14.8% |
| Net Margin % | - | -1.4% | 7.1% | 8.8% | 11.5% |
| ROE % | - | -1.5% | 9.3% | 10.8% | 13.0% |
| ROCE % | - | 3.6% | 12.1% | 12.6% | 13.0% |
Shareholding Pattern
Insiders
75.55%
Institutions
2.98%
Public Float
12.17%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SMSPHARMA
No recent headlines available.